Investment
Features
FeesSafety
Academy
More
Pluang+

Sun Communities to release Q3 2026 earnings on Oct 26, with conference call on Oct 27.

Company Fundamentals
19 Oct 2026
GlobeNewsWire
View Source
Neutral
Sun Communities to release Q3 2026 earnings on Oct 26, with conference call on Oct 27.

Sun Communities, Inc., a REIT specializing in manufactured housing and RV communities, announced it will release its third quarter 2026 earnings after market close on October 26, 2026. The company will hold a conference call to discuss the results on October 27, 2026, at 11:00 A.M. ET. Investors can access the live webcast and replay on the company's website. This update is important for shareholders and potential investors to assess the company's performance and outlook in the real estate sector focused on manufactured housing and RV properties.

Sun Communities, Inc. is set to announce its Q3 2026 earnings on October 26, 2026. For readers following the real estate sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 47 priced US real estate stocks, 10 rose and 37 fell. Notable movers include ARR at USD 12.30 with a -6.82% change and a typical hold time of 139 days, AGNC at USD 8.37 down 4.01% with 104 days hold time, and OPEN at USD 2.04 down 3.55% with a 33-day hold time.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App